Gemcitabine trials for Pancreatic Ductal Adenocarcinoma

All Gemcitabine trials · All Pancreatic Ductal Adenocarcinoma trials

Phase breakdown

Recruiting trials studying Gemcitabine for Pancreatic Ductal Adenocarcinoma

• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
  NCT07024615 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
  NCT04969731 · Phase: Phase 3 · Ages: 19 Years to 80 Years · Sex: All (male and female) · 1 location
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
  NCT05482893 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations

Common questions

How many trials study Gemcitabine for Pancreatic Ductal Adenocarcinoma?

11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.